Hikal soars as its Bengaluru API facility secures Swissmedic GMP certification
Hikal is currently trading at Rs. 212.35, up by 7.60 points or 3.71% from its previous closing of Rs. 204.75 on the BSE.
The scrip opened at Rs. 204.20 and has touched a high and low of Rs. 223.60 and Rs. 204.20 respectively. So far 108113 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 260.80 on 04-Dec-2025 and a 52 week low of Rs. 145.95 on 30-Mar-2026.
Last one week high and low of the scrip stood at Rs. 223.60 and Rs. 191.50 respectively. The current market cap of the company is Rs. 2651.58 crore.
The promoters holding in the company stood at 68.85%, while Institutions and Non-Institutions held 6.59% and 24.56% respectively.
Hikal’s active pharmaceutical ingredient (API) facility in Bengaluru has been granted a Certificate of GMP Compliance of a Manufacturer by Swissmedic, the Swiss Agency for Therapeutic Products. The certificate confirms that the facility meets the Good Manufacturing Practice (GMP) requirements of the Mutual Recognition Agreement between the European Union and Switzerland.
The Swissmedic certification builds on successful inspections of the Bengaluru facility by Brazil's ANVISA and Japan's PMDA. Together, these recognitions reinforce the site's standing with leading global regulators and position Hikal to serve a wider base of customers across regulated markets.
